Raised heart rate at discharge after acute heart failure is an independent mortality predictor.

Slides:

Advertisements

Similar presentations

The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.

Advertisements

חזק בהגנה לבבית Valsartan in Heart Failure

Hospitalizations for Severe Sepsis Among Elderly Medicare Beneficiaries William Buczko, Ph.D. Research Analyst Centers for Medicare & Medicaid Services.

Quality of Care and Outcomes in Patients with Diabetes Hospitalized with Ischemic Stroke Findings From Get With The Guidelines-Stroke Reeves MJ; Vaidya.

Spring 2015 ETM 568 Callier, Demers, Drabek, & Hutchison Carter, E. J., Pouch, S. M., & Larson, E. L. (2014). The relationship between emergency department.

CARDIOVASCULAR DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.

Hyperglycemia and Acute Coronary Syndromes. Cardiovascular disease and diabetes Bell DSH. Diabetes Care. 2003;26: Centers for Disease Control.

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Dr Sam Ley CT2 ICM Dr Radha Sundaram Consultant ICM Royal Alexandra Hospital, Paisley, Scotland.

Age-standardized mortality from ischaemic heart disease in European regions (men; age group years; year 2000) J Muller-Nordhorn, et al. Eur Heart.

Can we better protect patients who undergo revascularization? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing.

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.

以多重死因資料比較台灣美國腦中風併發吸入性肺炎之趨勢奇美醫學中心張嘉祐醫師. Stroke Statistics -- A Report From the American Heart Association Approximately 56% of stroke deaths in 2009.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.

Acute Renal Failure in Aneurysmal Subarachnoid Hemorrhage: Nationwide Analysis of Hospitalizations in the United States Kavelin Rumalla 1, Adithi Y. Reddy.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction by Mikhail Kosiborod, Saif S. Rathore, Silvio E. Inzucchi,

High heart rate: a cardiovascular risk factor? by Stéphane Cook, Mario Togni, Marcus C. Schaub, Peter Wenaweser, and Otto M. Hess EHJ Volume 27(20):

Figure 1 Patient flow chart.

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

R36: UTILISING FRAILTY EARLY WARNING SCORE (FEWS) IN THE ACUTE HOSPITAL SETTING TO IDENTIFY FRAIL AND VULNERABLE PATIENTS Lotte Dinesen1,2,Alan J Poots1,

Figure 1 Incidence and total numbers of SCD in patients with depressed LV systolic function and in patients with preserved LV function. The incidence of.

Copyright © 2009 American Medical Association. All rights reserved.

Death in hospital VA health care system (USA) Death within 1 year

Valsartan in Acute Myocardial Infarction Trial Investigators

Comparison of in‐hospital outcomes, including (A) technical failure, (B) postprocedural complications, (C) postprocedural hospital length of stay, and.

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

Adjusted relative mortality risk

Figure 4 BMI and mortality in patients with heart failure

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Heart Failure Management Coordinated Care Approaches

Baseline characteristics of patients

Oklahoma Foundation for Medical Quality

Figure 7 European Society of Cardiology 2016

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

Nat. Rev. Cardiol. doi: /nrcardio

OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

Biomarker-Guided HF Therapy: Is It Cost-Effective?

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Nat. Rev. Cardiol. doi: /nrcardio

Skilled Home Health Care: Do Patient’s Benefit?

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Volume 85, Issue 1, Pages (January 2014)

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

Continuing Adjuvant Tamoxifen to 10 Years

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Post-Heart Failure Mortality

Nat. Rev. Cardiol. doi: /nrcardio

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Simplified Markov diagram of a patient admitted to the ward with no respiratory support. Simplified Markov diagram of a patient admitted to the ward with.

Baseline Characteristics by hs-CRP

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Recurrence of HF hospitalization Total-time approach

Jeffrey Senfield et al. JACEP 2017;3:

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Characteristics of 3415 patients admitted to hospital with

Orly Vardeny et al. JCHF 2016;4:

Multivariate logistic regression for adjusted predictors of death during the initial hospitalization, 30 days and 1 year after injury for patients with.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Associations of dialysis session length with mortality and hospitalizations. Associations of dialysis session length with mortality and hospitalizations.

Presentation transcript:

Raised heart rate at discharge after acute heart failure is an independent mortality predictor

Objective: To analyze the relationship between heart rate at discharge and mortality in patients admitted for acute heart failure Methods: National survey in a randomized sample of 170 hospitals in France N = 1658 patients hospitalized for acute heart failure Logeart D et al; OFICA Study Group. [ESC abstract P2775]. Eur Heart J. 2012;33(abstract suppl):485.

Causes of one-year mortality One-year mortality after discharge is high One-year mortality = 32.9% Logeart D et al; OFICA Study Group. [ESC abstract P2775]. Eur Heart J. 2012;33(abstract suppl):485.

Raised heart rate at discharge after acute heart failure is an independent mortality predictor One-year mortality (%) P=0.028 Logeart D et al; OFICA Study Group. [ESC abstract P2775]. Eur Heart J. 2012;33(abstract suppl):485.

Take-home messages: 1.One-year mortality after discharge is high in patients admitted for acute heart failure. 2.More than half of deaths (56%) are due to heart failure and 16% due to sudden death. 3.Raised heart rate at discharge after acute heart failure is an independent mortality predictor and should be further taken into account in postdischarge management of heart failure patients. Logeart D et al; OFICA Study Group. [ESC abstract P2775]. Eur Heart J. 2012;33(abstract suppl):485.